Epigenetic evidence ties T-cell signaling to prematurity-related brain injury
A preprint from the University of Edinburgh adds a new immune layer to encephalopathy of prematurity, linking an epigenetic proxy of the T-cell-associated molecule CRTAM to neonatal brain abnormalities and later cognitive performance. The work uses DNA methylation-derived protein epigenetic scores as a window into circulating immune biology, and the signal that emerged was more specific than a generic inflammatory marker.
In 144 preterm infants, with a median gestational age at birth of 29+5 weeks and a range from 23+3 to 32+6 weeks, higher neonatal DNAm CRTAM tracked with worse microstructural brain measures at term-equivalent age. The association was not broad and indiscriminate. It centered on diffusion MRI features that are commonly interpreted as markers of white matter organization and developmental integrity.
White matter metrics moved in the direction of injury
Higher DNAm CRTAM was associated with a lower general factor of fractional anisotropy, with β = −0.252 and q = 0.011. In parallel, it was associated with higher general factors of radial diffusivity, mean diffusivity, and orientation dispersion index, with β values of 0.215, 0.198, and 0.201 and q values of 0.039, 0.047, and 0.048 respectively. Those are not abstract changes in imaging output; they point toward altered white matter maturation, reduced fiber coherence, and a less organized microstructural environment during a period when the preterm brain is still rapidly assembling its connectivity.
The same pattern did not appear to be explained away by the usual neonatal covariates. The associations held independent of inflammatory morbidities and other biological factors after false discovery rate correction. In a field where systemic illness, respiratory support, infection, and nutrition can all blur the readout, that persistence strengthens the argument that T-cell biology is carrying its own signal.
One sentence is hard to avoid: the immune signature was more informative than the generic inflammatory marker.
CRTAM carried more variance than C-reactive protein
The comparison with DNAm CRP sharpened the story. DNAm CRTAM explained more variance than DNAm CRP in diffusion MRI metrics, with a maximum incremental R2 of 4.2% versus 1.5%. The gap was even wider when cognition entered the picture. Higher neonatal DNAm CRTAM was associated with lower Mullen Scales of Early Learning Composite scores at 5 years, independent of DNAm CRP and the other covariates, with β = −0.332 and P = 0.008. It also explained more variance in childhood cognitive scores than DNAm CRP, with incremental R2 of 9.4% versus 1.2%.
That difference matters because C-reactive protein captures a nonspecific inflammatory burden, while CRTAM sits closer to T-cell activation and immune-cell interaction pathways. In practical biological terms, this points away from a purely generalized inflammatory model and toward a more selective immune mechanism in which lymphocyte dysregulation may influence oligodendrocyte development, axonal organization, or broader neuroimmune signaling during a vulnerable developmental window.
A specific immune pathway may be shaping neurodevelopment after preterm birth
The finding is especially relevant because preterm birth is already known to be strongly linked to systemic inflammation and later cognitive impairment. What this study adds is a candidate mechanism with better anatomical and developmental specificity. T cells are not just bystanders in peripheral immunity; they participate in brain-immune crosstalk across the life course, and the neonatal brain may be unusually sensitive to shifts in that dialogue. If CRTAM-related signaling reflects altered cytotoxic and regulatory T-cell activity, then immune imbalance could influence neonatal white matter development long before behavioral deficits become visible.
The imaging profile is consistent with that hypothesis. Lower fractional anisotropy together with higher radial and mean diffusivity often signals less efficient myelination or looser tissue architecture. Higher orientation dispersion index suggests more dispersed neurite orientation, which can reflect disrupted microstructural coherence. In a preterm infant at term-equivalent age, those changes fit the broad clinical concept of encephalopathy of prematurity, where the injury is often subtle on conventional imaging but consequential for later development.
What the preprint can and cannot claim
This was a multimodal prospective cohort study rather than an intervention trial, and the biomarker work relied on saliva DNA methylation proxies rather than direct measurement of circulating proteins. The cohort size was modest, even if carefully characterized, and the cognitive outcome was available only in a subset at 5 years. Those features do not weaken the biological signal, but they do define its limits. The data are associative, not causal, and they do not establish whether T-cell dysregulation drives the brain changes, accompanies them, or reflects a broader prenatal or postnatal immune milieu.
Even so, the internal consistency is compelling. The CRTAM proxy related to neonatal MRI metrics and later cognition, and it did so more strongly than a nonspecific marker of inflammation. That pattern argues for a more refined immune phenotype in the pathogenesis of atypical neurodevelopment after preterm birth, one that may eventually prove useful for risk stratification or mechanistic targeting if it holds in larger cohorts and independent datasets.
Why this immune signal could matter at the bedside
If these findings are replicated, they would support a shift in how prematurity-related brain injury is conceptualized. The neonatal brain would not be viewed only through the lens of oxygen delivery, infection, or generalized cytokine exposure. It would also be seen as a target of cell-specific immune programming, where T-cell dysregulation leaves a measurable imprint on white matter maturation and later learning. That could eventually influence biomarker development, trial design, and the selection of infants most likely to benefit from immune-informed neuroprotective strategies.
For now, the most defensible conclusion is narrower. An epigenetic proxy of CRTAM in preterm infants was associated with neonatal encephalopathy of prematurity and lower cognitive performance at 5 years, while explaining more variance than CRP. The next step is not speculation about treatment, but validation: larger cohorts, direct immune phenotyping, and longitudinal studies that can separate transient inflammation from durable T-cell dysregulation across early brain development.